Common mutations in human pancreatic cancer, including the proto-oncogene K-ras and the tumor suppressor genes CDKN2A, p53, and DPC4/SMAD4, can be exploited for development of PDAC GEMMs. This evidence concerns the gene KRAS and familial pancreatic carcinoma.